-
Aligos Therapeutics Inc. NASDAQ:ALGS Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Location: | Website: www.aligos.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-34.39M
Cash
94.54M
Avg Qtr Burn
-21.31M
Short % of Float
1.46%
Insider Ownership
20.07%
Institutional Own.
65.62%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ALG-097558 Details COVID-19 | Phase 2 Initiation | |
ALG-055009 (THR-β Agonist) Details Non-alcoholic steatohepatitis | Phase 2a Update | |
ALG-000184 (Capsid Assembly modulator) Details Chronic hepatitis B | Phase 1 Data readout | |
ALG-010133 (S-antigen Transport-inhibiting Oligonucleotide Polymer) Details Chronic hepatitis B | Failed Discontinued | |
ALG-125755 Details Chronic hepatitis B, Liver disease | Failed Discontinued |